The P-selectin and PSGL-1 axis accelerates atherosclerosis via activation of dendritic cells by the TLR4 signaling pathway

Zhishuai Ye1,2, Lei Zhong2, Shengnan Zhu2, Yinuo Wang2, Jie Zheng2, Shujing Wang3, Jianing Zhang4 and Rongchong Huang1,2

Abstract
P-selectin and dendritic cells (DCs) are associated with atherosclerosis. However, their interactions in this setting are undefined. Herein, we investigated the role of P-selectin and its receptor P-selectin glycoprotein ligand (PSGL)-1 on atherosclerosis via activation of DCs. In the current study, a total of 34 patients with ST elevation myocardial infarction (STEMI) and 34 healthy control subjects were enrolled. Serum concentration of P-selectin was higher and the myeloid DC/plasmacytoid DC (mDC/pDC) ratio was lower in STEMI patients than in normal individuals. Interestingly, in STEMI patients, P-selectin was decreased and the mDC/pDC ratio was increased at 5–7 days after successful percutaneous coronary intervention, as compared with values on admission. Serum P-selectin was inversely correlated with the mDC/pDC ratio. Moreover, ApoE−/−P−/− and ApoE−/−PSGL-1−/− mice developed small atherosclerotic plaques after feeding of a western diet for 12 weeks and DC infiltration was significantly reduced. P-selectin stimulation markedly induced phenotypic maturation, enhanced secretion of inflammatory cytokines, communication with T cells, and the adhesion and migration of DCs. In vivo, DC maturation was significantly attenuated in P-selectin and PSGL1 knockout mice under hypercholesterolemic and inflammatory conditions. These effects were associated with the activation of myeloid differentiation primary response 88 (MYD88)-dependent and MyD88-independent Toll-like receptor 4 (TLR4) signaling pathways. Taken together, binding of P-selectin to PSGL-1 on DCs contributes to atherosclerosis progression via DC activation via the TLR4 signaling pathway.

Introduction
Dendritic cells (DCs) have been identified in the normal arterial wall and within atherosclerotic lesions in atherosclerosis, an inflammatory disease with incompletely characterized underlying mechanisms1,2. As the most powerful and specialized antigen-presenting cells, DCs link innate and acquired immunity3, and exist mostly in an immature form in the periphery with maturation being key for function4. In higher numbers in late vs. early plaque stages and in acute coronary syndromes, other than stable angina, DCs locally infiltrate atherosclerotic plaques and may influence the accumulation in plaque shoulders, which rupture relatively easily5,6.

Selectins are cell adhesion molecules that mediate the adhesion of inflammatory cells to vascular surfaces and to each other7. P-selectin, which is expressed on the surface of activated platelets and endothelial cells, activates platelets by interacting with the P-selectin glycoprotein ligand (PSGL)-1, which promotes thrombosis and further inflammation, thereby accelerating atherosclerotic plaque formation8,9. These possible roles of P-selectin in atherogenesis are further underscored by its higher surface expression on platelets in acute coronary syndromes other
than stable angina\(^\text{10}\), and mitigation of myocardial injury by the P-selectin antagonist inclacumab in patients with ST-segment elevation myocardial infarction (STEMI) undergoing percutaneous coronary intervention (PCI)\(^\text{11}\).

Toll-like receptor 4 (TLR4) is expressed on different subsets of immune cells and its function is regulated in a cell-type-specific manner. Activation of TLR4 contributes to the maturation and regulation of antigen presentation of DCs, as well as T-cell differentiation\(^\text{12}\). Ozaki et al. reported that the expression levels of PSGL-1 on inflammatory monocytes were high in acute coronary syndrome patients and positively correlated with TLR4 expression\(^\text{13}\). The results of our previous study showed that L-selectin promoted the maturation of DCs via up-regulation of TLR4 signaling pathway and consequently promote the progression of atherosclerosis.

**Results**

**Serum concentration of P-selectin was increased and the mDC/pDC ratio was decreased in STEMI patients**

Thirty-four patients with STEMI and 34 aged-matched healthy controls were included for analysis. The blood concentrations of P-selectin, myeloid DCs (mDCs), and plasmacytoid DCs (pDCs) were measured on admission and at 5–7 days after PCI. As shown in Table 1, STEMI patients had higher mean white blood counts, greater high-sensitivity C-reactive protein (hs-CRP) and B-type natriuretic peptide serum concentrations, and lower left ventricular ejection fractions. The serum concentrations of P-selectin and TNF-α were higher in the STEMI group vs. controls (6.66 ± 0.09 vs. 5.10 ± 0.71 ng/mL, \(p < 0.0001\); 79.7 ± 47.9 vs. 52.0 ± 39.0 pg/mL, \(p = 0.0110\)). The proportion of mDCs, as a percentage of total white blood cells, was lower in STEMI patients vs. controls (0.68 ± 0.10% vs. 1.91 ± 0.16%, \(p < 0.0001\)) or as the absolute count (42.20 ± 6.17/µL vs. 141.1 ± 12.60/µL, \(p < 0.0001\)). By contrast, there was no significant difference in pDC counts between groups (\(p = 0.1869\)). Meanwhile, the circulating mDC/pDC ratio was lower in STEMI patients vs. controls (5.83 ± 1.23 vs. 14.37 ± 2.04, \(p = 0.0006\); Fig. 1b).

However, as compared with the STEMI group on admission, serum P-selectin was decreased at 5–7 days after successful PCI (6.66 ± 0.16 vs. 5.09 ± 0.12 ng/mL, \(p < 0.0001\)), while the percentage and absolute count of mDCs were both increased (0.68 ± 0.56% to 1.24 ± 0.77%, \(p = 0.0005\); and 42.20 ± 6.17/µL to 110.7 ± 14.27/µL, \(p < 0.001\), respectively; Fig. 1c). In addition, the circulating mDC/pDC ratio also increased from 5.83 ± 1.23 to 12.79 ± 2.84 in the STEMI group and was inversely correlated with serum P-selectin levels in STEMI patients on admission (\(r = -0.5133, p = 0.0019\)), 5–7 days after successful PCI (\(r = -0.6709, p < 0.0001\)), and in total (\(r = -0.3840, p = 0.0012\)). However, no statistically significant correlation was found in the controls (Fig. 1d).

Taken together, we hypothesized that P-selectin plays a critical role in the migration of circulating mDCs into inflammatory vessels, which is a possible reason for the decrease in circulating mDCs in STEMI on admission.

| Table 1 Clinical characteristics of the study population on admission |
|-----------------|-----------------|-----|
|                 | Controls (n = 34) | STEMI patients (n = 34) | \(p\) |
| Age (y)         | 60.6 ± 8.9      | 62.9 ± 14.7 | 0.4397 |
| Males, n (%)    | 22 (64.7%)      | 27 (79.4%) | 0.2796 |
| Body-mass index (kg/m\(^2\)) | 24.8 ± 2.5 | 24.1 ± 1.8 | 0.1898 |
| Hypertension, n (%) | 17 (50.0%) | 18 (52.9%) | 1.0000 |
| Diabetes mellitus, n (%) | 5 (27.8%) | 8 (30.7%) | 0.5387 |
| Current smoker, n (%) | 12 (35.3%) | 19 (55.9%) | 0.1435 |
| Systolic blood pressure (mmHg) | 133 ± 13 | 129 ± 28 | 0.4526 |
| Diastolic blood pressure (mmHg) | 81 ± 9 | 78 ± 17 | 0.3664 |
| Total cholesterol (mmol/L) | 4.4 ± 0.8 | 4.8 ± 1.0 | 0.0731 |
| Total triglyceride (mmol/L) | 1.6 ± 1.3 | 1.4 ± 0.9 | 0.7135 |
| LDL-cholesterol (mmol/L) | 2.6 ± 0.6 | 2.9 ± 0.8 | 0.0849 |
| HDL-cholesterol (mmol/L) | 1.3 ± 0.4 | 1.2 ± 0.3 | 0.2477 |
| Creatinine (µmol/L) | 766 ± 15.7 | 840 ± 39.3 | 0.3116 |
| Thyroid stimulating hormone (mU/L) | 1.3 ± 1.1 | 1.2 ± 1.0 | 0.6962 |
| Aspartate aminotransferase (U/L) | 31.5 ± 61.7 | 51.6 ± 47.5 | 0.2364 |
| White blood cell count \((x10^9/L)\) | 6.7 ± 23 | 10.7 ± 2.5 | <0.0001 |
| B-type natriuretic peptide (ng/L) | 43.3 ± 43.0 | 260.1 ± 377.8 | 0.0014 |
| Left ventricular ejection fraction (%) | 59.0 ± 2.5 | 51.6 ± 7.2 | <0.0001 |
| hs-CRP (mg/L) | 2.2 ± 3.5 | 25.2 ± 41.1 | 0.0018 |
| TNF-α (pg/mL) | 52.0 ± 39.0 | 79.7 ± 47.9 | 0.0110 |

Data are presented as n (%) or mean ± SD. STEMI ST-segment elevation myocardial infarction, LDL-cholesterol low-density lipoprotein, HDL-cholesterol high-density lipoprotein, hs-CRP high-sensitivity C-reactive protein, TNF-α tumor necrosis factor-α.
Effect of P-selectin-PSGL on the immunogenic capability of DCs

To determine the intrinsic effect of P-selectin-PSGL engagement on the immunogenic capability of DCs, human DCs were isolated from CD14$^+$ peripheral blood mononuclear cells and differentiation was induced by rhIL4 and rhGM-CSF. Then, DCs without transfection or transfected with negative control siRNA or GALNT4 siRNA were treated with bovine serum albumin as a control, LPS (20 ng/mL), P-selectin (100 ng/mL), or...
P-selectin plus KPL1 (5 μg/mL) for 24 h, respectively. First, the maturation surface molecular markers of DCs, including CD80, CD86, and MHC-II, were monitored by flow cytometry. As shown in Fig. 2a, b, pretreatment with LPS and P-selectin significantly induced maturation of DCs, as compared with the control group, while
pretreatment with the PSGL1 Ab KPL-1 and PSGL1 knockdown of DCs had partially reversed the effect of P-selectin. Functionally, DCs treated with P-selectin acquired the capacity to enhance allogeneic T cell proliferation as effectively as LPS treatment in the mixed lymphocyte reaction (MLR) assay, while pretreatment with KPL-1 or knockdown of PSGL1 rendered the DCs unable to stimulate allogeneic T cells even with P-selectin stimulation (Fig. 2c, d). In addition, stimulation with LPS profoundly increased the ability of human DCs to adhere to the human umbilical vein endothelial cell (HUVEC) monolayer. Moreover, treatment with P-selectin increased human DC adhesion, while DC adhesion induced by P-selectin was almost completely abolished by treatment with KPL1 and PSGL1 knockdown (Fig. 2e, f). Accordingly, the results of the transwell migration assay showed that P-selectin significantly increased the migration of DCs, while treatment with KPL1 or knockdown of PSGL1 attenuated these changes (Fig. 2g, h). Interestingly, PSGL1 knockdown did not influence the effect of LPS on phenotypic maturation, communication with T cells, adhesion, or migration of DCs (data not shown).

**P-selectin-PSGL1 deficiency suppresses DC maturation under hypercholesterolemic and inflammatory conditions in vivo**

To further evaluate the effect of P-selectin-PSGL1 on DC maturation under in vivo hypercholesterolemic conditions, ApoE−/−, ApoE−/−PSGL1−/−, and ApoE−/−P−/− mice were fed a western diet for 12 weeks. Afterward, the splenic CD11c+ cells were analyzed for signs of DC maturation. As compared with ApoE−/− mice, expression of the phenotypic maturation markers of DCs, including CD86 and MHC-II, were significantly increased in ApoE−/−PSGL1−/− and ApoE−/−P−/− mice (Fig. 3a). To further confirm the suppression of DC maturation, the serum levels of TNF-α, IL-6, and IFN-β were measured and found to be significantly decreased in both double knockout mice (Fig. 3b). In addition, both double knockout mice were found to be enriched in CD45CD11bLy6Chigh inflammatory monocytes counts were significantly reduced (unpublished data).

We next determined whether P-selectin-PSGL1 influences DC maturation under inflammatory conditions. WT and PSGL1−/− mice were subcutaneously infused with P-selectin (5 mg/kg), NS, or LPS (1 mg/kg) for 1 day. As shown in Fig. 3c, WT mice displayed higher expression levels of CD86 and MHC-II on splenic DCs after treatment with P-selectin and LPS than the mice treated with NS, while P-selectin-induced DC maturation was almost inhibited in PSGL1−/− mice (Fig. 3e). Furthermore, qRT-PCR confirmed that P-selectin induced up-regulation of IL-6, TNF-α, and IFN-β at the mRNA level in spleen tissue (Fig. 3d). In contrast, there was no significant difference in IL-6, TNF-α, and IFN-β mRNA levels between the PSGL1−/− mice treated with NS and those treated with P-selectin, or the expression of CD86 and MHC-II on splenic DCs, while the mRNA levels of the above cytokines and the maturation surface markers of DCs were all significantly increased in PSGL1−/− mice treated with LPS (Fig. 3e, f). These data demonstrate that P-selectin contributed to the activation and the maturation of DCs, while deletion of PSGL1 or P-selectin suppressed splenic DC maturation and activation in response to hypercholesterolemia and inflammation.

**Knockout of P-selectin or PSGL1 attenuated the development of atherosclerosis**

To investigate the effect of P-selectin and PSGL-1 on the development of atherosclerosis, ApoE−/−, ApoE−/−P−/−, and ApoE−/−PSGL-1−/− mice were fed a western diet for 12 weeks. As shown in Supplemental Table S1, there were no significant differences in plasma lipid levels among the ApoE−/−, ApoE−/−P−/−, and ApoE−/−PSGL-1−/− mice. As compared with ApoE−/− mice, ApoE−/−P−/−, and ApoE−/−PSGL-1−/− mice developed smaller atherosclerotic lesions, as determined by en face staining and Oil red O staining (Fig. 4a). Hematoxylin and eosin (H&E), Movat, and Masson staining indicated that both double knockout mice had smaller lesion size and necrotic areas, more collagen content, as compared with ApoE−/− mice (Fig. 4b). The decreases of the plaque and necrotic areas and the increase in the collagen content in both double knockout mice may be associated with plaque stability. In addition, the number of DCs infiltrating into the lesions of ApoE−/−P−/− and ApoE−/−PSGL-1−/− mice was significantly less than in the lesions of ApoE−/− mice (Fig. 4c). Meantime, plaque infiltration by monocytes/macrophages and lymphocyte CD4 T cells was impaired in two double knockout mouse strains (Fig. S3). Thus, these findings indicate the important roles of PSGL-1 and P-selectin in mediating the recruitment of DCs into atherosclerotic lesions and the development of early atherosclerosis.

**P-selectin induced DC activation through MyD88-dependent TLR4 signaling**

The TLR4 and nuclear factor (NF)-κB signaling pathway is essential to induce the maturation of DCs with upregulation of costimulatory molecules and T cell-dependent immune responses. We first analyzed the phosphorylation status of IKKα/β, IκBα, and NF-κB p65 in human DCs treated with P-selectin at different time points (0, 10, 20, 40, and 80 min). Our results showed that at 20 min, P-selectin significantly induced the phosphorylation of NF-κB p65 and IKKα/β, and promoted IκBα degradation and phosphorylation of IκBα (Fig. S3A). Meanwhile, P-selectin significantly induced MyD88-dependent TLR4 signaling
Fig. 3 P-selectin-PSGL-1 deficiency suppresses DC maturation under hypercholesterolemic and inflammatory conditions in vivo. ApoE−/−, ApoE−/−P−/−, and ApoE−/−PSGL-1−/− mice were fed a western diet for 12 weeks. 

a. Representative flow cytometric dot plots showing the percentage of CD11c+ DCs expressing the DC maturation marker CD86 or MHC-II in spleen tissue. 

b. ELISA analysis of the indicated cytokine levels in serum. WT and P-selectin−/− mice were subcutaneously infused with P-selectin, NS, or LPS for 1 day. 

c, d. Representative flow cytometric dot plots showed the percentage of CD11c+ DCs expressing the DC maturation marker CD86 or MHC-II in spleen tissue. 

e, f. qRT-PCR analysis of the indicated cytokine mRNA levels in spleen tissue. Data are expressed as the mean ± SD (n ≥ 5). *p < 0.05, **p < 0.01, ***p < 0.001
Fig. 4 (See legend on next page.)
and increased the phosphorylation of p38, JNK, and IRAK4 (Fig. S3B). After pretreatment with KPL1, PSGL1 knockdown of the DCs was performed. The results showed that P-selectin and LPS significantly increased the phosphorylation of IKKα/β, IκBα, and NF-κB p65, as well as the intensity of TLR4-induced MyD88-dependent phosphorylation of p38, JNK, and IRAK4, while pretreatment with KPL1 and knockdown of PSGL1 remarkably attenuated P-selectin-induced phosphorylation of these molecules (Fig. 5a, b). Consistent with these data, P-selectin significantly increased DC secretion of IL-6 and TNF-α, while the addition of KPL1 and knockdown of PSGL1 significantly decreased P-selectin-induced up-regulation of IL-6 and TNF-α (Fig. 5c, d). Similar to human DCs in vitro, the atherosclerotic plaques of ApoE−/−/P−/− and ApoE−/−/PSGL−1−/− mice exhibited less positive staining of MyD88, phospho-IRAK4, and phospho-NF-κB p65 than was observed in ApoE−/− mice (Fig. 5e).

**P-selectin induced DC activation through TRIF-dependent TLR4 signaling**

TLRs generally signal via the MyD88-dependent pathway, leading to a proinflammatory response. Conversely, the MyD88-independent pathway involves TRIF, which activates IRF3 leading to the subsequent production of type I IFN16,17. We found that P-selectin induced an increase in the protein levels of TRIF and the phosphorylation of IRF3, which started at 10 min and reached a maximum at 40 min (Fig. S4C). In addition, KPL1 pretreatment or knockdown of PSGL1 on DCs significantly inhibited P-selectin-induced expression of TRIF, as well as the phosphorylation of IRF3 and secretion of IFN-β (Fig. 6a–d). Moreover, as compared with ApoE−/− mice, the plaques of ApoE−/−P−/− and ApoE−/−PSGL−1−/− mice contained less TRIF and phospho-IRF3 (Fig. 6e).

**Discussion**

The present study provides insight into the characterized role of P-selectin–DC interactions in atherosclerosis, with P-selectin accelerating disease progression by promoting DC maturation. Notably, as compared with normal controls, the mDC/pDC ratio was lower and serum P-selectin content was higher in STEMI. Furthermore, P-selectin was decreased and the mDC/pDC ratio was increased at 5–7 days after successful PCI as compared with values on admission. P-selectin or PSGL1 deficiency clearly attenuated the development of atherosclerosis when these mice were crossed into an ApoE−/− background. Although these results are consistent with those of previous reports18–21, we further found that the absence of PSGL1 or P-selectin inhibited the maturation of DCs under hypercholesterolemic and inflammatory conditions, and impaired homing of CD11c+ DCs to atherosclerotic lesions. We also provide evidence that P-selectin stimulation markedly induced DC maturation, secretion of inflammatory cytokines, communication with T cells, adhesion, and migration, and further activated the TLR4 signaling pathways.

DCs are present in high numbers in the atherosclerotic vessel wall, where they can interact with T cells, macrophages, and smooth muscle cells to promote the release of cytokines and trigger and regulate adaptive immune responses2–23. Our previous data and that of other researchers have demonstrated that the amounts of circulating DCs and precursor cells are decreased in patients with heart disease24–26. One possibility for the decrease in circulating DCs might be their enhanced recruitment to the disease site. Interestingly, Shimomura’s group found that the plasma level of soluble P-selectin peaked significantly at 4 h in patients with acute myocardial infarction after initiation of reperfusion therapy, suggesting that the increase in P-selectin levels may be caused by activation of endothelial cells and platelets after myocardial ischemia or infarction27. The results of the present study showed that the amount of circulating mDCs was reduced in STEMI patients on admission but had increased at 5–7 days after PCI, while pDC numbers were not significantly altered. Moreover, the number of circulating mDCs was inversely correlated with P-selectin. Recently, DCs have been further divided into two subsets, including conventional mDCs and pDCs. mDCs are activated by exogenous and endogenous danger signals binding to TLR2 and TLR428, which further trigger the recruitment of cytotoxic T cells via production of IL-12. Thus, mDCs play a critical role in atherogenesis and, in particular, plaque destabilization, which ultimately leads to plaque rupture29, whereas the role of pDCs during atherogenesis remains controversial. pDCs are mainly activated by viral...
antigens binding to intracellular receptors, such as TLR9, and produce type I IFN, which is triggered by stimulation of plaque tissue with CpGs in vitro, upregulation of TLR4 on cDCs, and tumor necrosis factor–related apoptosis-inducing ligand by CD4+ T cells, resulting in the killing of plaque-resident cells28,30. In contrast, pDC-depletion using an antibody against BST2 aggravated atherosclerotic lesion development in carotid arteries in LDLR−/− mice, which is attributed to the loss of indoleamine 2,3-dioxygenase-dependent restraint of T-cell proliferation31. Owing to the existence of two distinct subtypes of DCs with different functions, the migration of circulating mDCs into atherosclerotic plaques may be largely mediated by P-selectin, which is a possible reason for the decrease in circulating mDCs in STEMI. Furthermore, we found that P-selectin enhanced the adhesion and migration abilities of human DCs, while a deficiency of PSGL1 or P-selectin reduced the accumulation of DCs in atherosclerotic lesions.

Fig. 5 P-selectin induced DC activation through MyD88-dependent TLR4 signaling. DCs were treated as described in the legend of Fig. 2. a, b Representative western blots showing expression levels of total and phospho-iKKa/β, total and phospho- IkBα, total phospho-NF-κB p65, total and phospho-P38, total and phospho-JNK, and total and phospho-IRAK4. The intensities of the protein bands were quantified and presented as the ratio of phosphorylated protein/total protein vs. controls after normalization to GAPDH (n = 3). c, d ELISA analysis of the TNF-α and IL-6 levels in the supernatants of DC culture medium (n = 3). e Immunohistochemical analysis of MyD88, phospho-IRAK4, and phospho-NF-κB p65 in atherosclerotic lesions of mice (n = 8). Scale bar: 200 and 50 μm, respectively. Data are expressed as the mean ± SD. *p < 0.05, **p < 0.01, ***p < 0.001

Of examinees and the Cell Death Differentiation Association
and differentiation of immune cells, as with monocytes/macrophages and lymphocyte T cells. We can not deny that the limitation of using global PSGL1 and P-selectin-null mice in this study, which is insufficient to clarify the precise role of DCs in atherosclerosis, thus a conditional knockout approach will be employed in future studies.

DCs are currently known as the most potent antigen-presenting cells. The majority of DCs in vivo are in an immature state with low expression of the cell surface costimulatory molecules CD80 and CD86 as well as MHC-II, which are required for the stimulation of T cells. However, DCs undergo a series of phenotypic and functional maturations in response to various stimuli. At atherothrombosis sites, inflammatory stimulation, such as platelet degradation, leads to the rapid redistribution of P-selectin to the cell surface, where it binds to leukocyte PSGL-1, thereby contributing to cell adhesion, particularly associated with leukocyte rolling along the endothelial cell surface. It is reported that PSGL-1 is broadly expressed on the surface of DCs and the regulation of O-glycosylation on PSGL1 was associated with the maturation of immature DCs and the migration of mature DCs. In general, PSGL-1 has long been studied as an adhesion molecule involved in immune cell trafficking, which is considered as a relatively new player in the immune checkpoint landscape. Several studies have demonstrated that PSGL1 plays a critical role in the regulation of myeloid cell differentiation into lymphocytes, monocytes, and neutrophils. The regulatory role of PSGL-1 was also identified in DCs. Urzainqui et al. reported that PSGL-1 could act as an immune tolerant receptor for human and mouse DCs. In addition, the use of a P-selectin Ab had an inhibitory effect on DC maturation. Consistent with this observation, our results suggest that P-selectin has profound regulatory effects on the activation and function of DCs, where engagement of P-selectin or anti-PSGL-1 induces the secretion of IL-6, TNF-α, and IFN-β, which are associated with immune activation, and promoted the ability to induce CD4+ T cells.

In addition to regulating the migration of leukocytes into inflammation sites, PSGL1 also functions as a cell...
signaling transmembrane receptor. PSGL-1 activates intracellular protein kinases, such as mitogen-activated protein kinase, which controls the expression of various pro-inflammatory cytokines. Targeting P-selectin and PSGL1 interactions holds significant potential for the treatment of inflammatory disorders. TLR4 receptor is abundantly present on the surface of DCs and is involved in the formation of foam cells and promotion of atherosclerotic plaque formation. Studies have shown that DC maturation is associated with NF-κB signal transduction and gene transcription, as main regulators of TLR4 gene expression. The binding of TLR4 to its ligand as well as a series of downstream signal transduction molecules can activate DC maturation, and further mediate the homing and accumulation of DCs at epithelial sites. The results of this study suggest that PSGL1 is a potent mediator of both MyD88-dependent and TRIF-dependent TLR4 signaling in P-selectin-stimulated DCs. In the absence of PSGL1, DCs are in a state with lower expression of costimulatory molecules and poor induction of T-cell responses, as well as impaired TLR4 signaling after stimulation of P-selectin. Interestingly, the absence of PSGL1 did not influence the binding of LPS to TLR4 or the stimulation of DCs. Recently, Ling et al. found that CD11b (integrin αMβ2) facilitates LPS binding to TLR4 and controls the trafficking and signaling functions of TLR4 in DCs. Meanwhile, the engagement of P-selectin to PSGL1 induces an intermediate state of αMβ2 activation. Therefore, we presumed that PSGL1 may have an indirect role in connection with TLR4 in DCs. However, further investigations are required to address this hypothesis.

**Conclusion**

In summary, the present study of the first to demonstrate that P-selectin binds to PSGL-1 on the surface of DCs, which promoted DC maturation by the TLR4/NF-κB signaling pathway, which along with a variety of inflammatory factors contributed to the development and progression of atherosclerosis.

**Materials and Methods**

**Human study populations**

The study cohort included 34 patients with STEMI who were treated at the First Affiliated Hospital of Dalian Medical University (Dalian, China) between September 2016 and December 2016. Diagnoses were based on the 2014 ACC/AHA Guidelines for the Management of Patients with ST-segment Elevation Acute Coronary Syndromes. The study protocol conformed to the principles of the Declaration of Helsinki, was approved by the Ethics Committee of the First Affiliated Hospital of Dalian Medical University, Dalian City, P.R. China (LCKY2016-6), and was registered with www.clinicaltrials.gov as NCT02896543. Study inclusion criteria were: duration of chest pain < 24 h; 18–80 years old; left ventricular ejection fraction ≥ 45% as determined by echocardiography; and signed informed consent documents. Exclusion criteria were as follows: (1) abnormal hematopoietic function, such as platelets < 100 × 10⁹/L or > 700 × 10⁹/L or white blood cells < 3 × 10⁹/L; (2) complicated with other organ failure or severe diseases, such as severe renal insufficiency (glomerular filtration rate < 60 ml/min·1.73 m²), severe liver injury (aspartate transaminase or alanine aminotransferase higher than 3-fold the normal upper limit), severe congestive heart failure (heart function of grade IV), acute and chronic infectious diseases, immune system diseases, asthma, cancer, and other late-stage diseases; (3) women who were pregnant or planning to become pregnant; (4) allergic or intolerant to drugs used for myocardial infarction, such as aspirin, clopidogrel, statins, angiographic agents, anticoagulant drugs, stent coated drugs, and stainless steel; (5) cognitive dysfunction, or severe hearing or visual impairment that may influence normal communication, as well as patients who rejected follow-up; and (6) patients who were participating in other drug or medical device clinical trials and had not achieved primary endpoints, or those who planned to participate in other drug or medical device clinical trials within 12 months after surgery. The control group consisted of 34 age-matched subjects without coronary artery disease based on coronary angiography performed at our hospital during the same period. Patients and controls with previous myocardial infarction, abnormal hematopoietic function, autoimmune diseases, malignancies, chronic or acute infections, severe heart failure, and advanced liver or renal diseases were excluded.

**Cells**

Human peripheral blood CD14⁺ monocytes were isolated using CD14⁺ immunomagnetic beads (Miltenyi Biotec, Bergisch-Gladbach, Germany) and then cultured for 5 days in complete medium containing 100 ng/mL of recombinant human granulocyte-macrophage colony stimulating factor (rhGM-CSF; PeproTech, Inc., Rocky Hill, NJ, USA) and 50 ng/mL of recombinant human interleukin 4 (rhIL4; PeproTech). Human CD4⁺ T cells were isolated from peripheral blood monocytes by positive selection with CD4⁺ immunomagnetic beads (Miltenyi Biotec). Primary HUVECs were purchased from ScienCell Research Laboratories (Carlsbad, CA, USA), cultured in endothelial cell medium (ScienCell), and maintained at 37°C under 5% CO₂ in a humidified incubator. The growth medium was changed every 2 days.

**Mice**

ApoE-deficient mice (B6.129P2-Apoetm1unc/J), PSGL-1-deficient mice (B6.Cg-Selplgtm1Fur/J), and P-selectin-
deficient mice (B6.129S7-Selptm1Bay/J) were purchased from the Jackson Laboratory (Bar Harbor, ME, USA). ApoE/PSGL-1/-/-deficient mice were generated by crossing PSGL-1/-/- mice with ApoE/-/- mice, and ApoE/-/P/-/-deficient mice were generated by crossing P/-/-mice with ApoE/-/- mice. The genotype of all mice was identified by polymerase chain reaction (PCR), as shown in Supplemental Fig. 1. Mice were housed in a specific pathogen-free facility. The protocols of all mouse experiments were approved by the Institutional Animal Care and Use Committee of Dalian Medical University (approval no. L2014030).

Transfection
Small interfering RNA (siRNA) duplex oligonucleotides specific for PSGL1 were synthesized by GenePharma Co., Ltd. (Suzhou, China) with the following sequences: siNC: 5'-UUC UCC GAA CGU GUC ACG UTT-3'; siPSGL1(1): 5'-GAC CUU UCU UUG GGA CUG UTT-3'; siPSGL1 (2): 5'-GUG CAG GCA AUA AUG UTT-3'; siPSGL1(3): 5'-CGG ACC AUA UUC CCU UCA ATT-3'. On day 4, human DCs were seeded into six-well plates until 70% confluence and then transfected with 100 nM siRNA with Lipofectamine RNAi MAX reagent (Invitrogen Corporation, Carlsbad, CA, USA) in accordance with manufacturer’s instructions. After transfection for 48 h, RNA and protein samples were collected for quantitative real-time PCR (qRT-PCR) and western blot analyses (Fig. S2).

Atherosclerosis and Splenic DC stimulation in vivo
Eight-week-old male ApoE/-/P/-/-, ApoE/-/-/PSGL1/-/-, or ApoE/-/- mice were fed a western diet (21% fat + 0.15% cholesterol). At the end of 12 weeks of treatment, the mice were euthanized and the brachiocephalic trunks and blood samples were collected for analysis. For splenic DC stimulation, wild-type (WT), PSGL1/-/-, TLR4/-/-, and MyD88/-/- mice were subcutaneously (s.c.) injected with P-selectin at 5 mg/kg (R&D Systems, Minneapolis, MN, USA) for 1 day. Mice were s.c. infused with normal saline as a negative control group or treated with liposaccharide (LPS; 1 mg/kg; Sigma-Aldrich Corporation, St. Louis, MO, USA) as a positive control group. Three days later, the mice were killed and the spleens were collected. Single-cell suspensions were prepared and then analyzed by flow cytometry.

Histological study
Aortic roots from ApoE/-/-, ApoE/-/-P/-/-, and ApoE/-/-PSGL1/-/- mice were embedded in 10% buffered formalin, and 5-µm-thick serial sections were prepared and then stained with H&E to analyze lesions. Masson’s trichrome stain was used to delineate the collagen content. Movat staining was performed to identify necrotic areas of the atherosclerotic lesions. Atherosclerotic lesions stained with Oil red O and quantified by en face analysis of the whole aorta.

Immunostaining
Slides of aortic sinus sections were incubated with 0.3% H2O2 for 15 min to remove endogenous peroxidases, blocked with 5% bovine serum albumin at room temperature for 45 min, and then incubated overnight at 4°C in a wet chamber with primary antibodies (Abs) against CD68, CD4, MyD88, TRIF, phospho-IRAK4, phospho-NF-κB p65, and phospho-IRF3 (Abcam, Cambridge, UK; all diluted to 1:100). After washing with phosphate-buffered saline, the slides were incubated with secondary Abs for 30 min and then visualized with diaminobenzidine. DCs in the sections were examined using an Alexa Fluor® 647-conjugated anti-CD11c Ab (1:50; Novus Biologicals LLC, Littleton, CO, USA). Control immunostaining was performed using the respective nonimmune IgG. Quantification of positive areas was performed using Image-Pro Plus 6.0 software (Media Cybernetics, Inc., Silver Spring, MD, USA).

Cytokine and lipid analysis
Human serum levels of P-selectin and DC supernatant levels of tumor necrosis factor (TNF)-α, interleukin (IL)-6, and interferon (IFN)-β, and mouse serum levels of TNF-α, IL-6, IFN-β, and lipid profiles were measured using enzyme-linked immunosorbent assay (ELISA) kits (Abcam) and a cholesterol assay kit (Abcam), following the manufacturer’s instructions.

RNA isolation and qRT-PCR
Total RNA was extracted from cells and tissues using RNAiso Plus total RNA extraction reagent (Takara Bio, Inc., Shiga, Japan) and complementary DNA was synthesized using a qRT-PCR kit (Takara) according to the manufacturer’s recommendations, using the following primer sequences: human glyceraldehyde 3-phosphate dehydrogenase (GAPDH) forward: 5'-CCA TGG AGA AGG CTG GGG-3', reverse: 5'-CAA AGT TGT CAT GGA TGA CC-3'; human PSGL1 forward: 5'-GCC TCC TGT TGC TGA TCC TAC TG-3', reverse: 5'-TAC TCA TAT TCG GTG GCC TGT CT-3'; mice GAPDH forward: 5'-GCG CCT GGT GCT GGC TCT-3', reverse: 5'-TAC TGA GGC TCC CCC CCA AGA-3'; mice IL-6 forward: 5'-TAG TCC TTC CTA CCC CAA TTT C-3', reverse: 5'-TAG TGG CTT AGC CAC TCC TTC-3'; mice TNF-α forward: 5'-TAG TCC TCC TCC TCT CAA TG-3', reverse: 5'-TAG CTT TTC CTA CCA CCC CAA AC-3', reverse: 5'-TGG CTT CTG TTT TGC AA-3'; mice IFN-β forward: 5'-TTC CAC AGC CCT CTC CTC-3', reverse: 5'-CAT CTT CTC GTG CAT CTC CAT AG-3'. Relative changes in mRNA expression were normalized to that of GAPDH using the 2^-ΔΔCt method.
Flow cytometry

The following Abs were purchased from Becton Dickinson (San Diego, CA, USA; all diluted to 1:50): human phycoerythrin (PE) anti-CD11c, fluorescent isothiocyanate (FITC) anti-major histocompatibility complex (MHC) class II, FITC anti-CD80, FITC anti-CD86, PE anti-IL-3 receptor a (CD123), peridinin chlorophyll protein anti-human leukocyte antigen (HLA)-DR, FITC lineage cocktail 1 [lin1, contains monoclonal Abs CD3 (T cells), CD14 (monocytes/macrophages), CD16 (natural killer cells), CD19 (B cells), and CD56 (natural killer cells)], mouse FITC anti-MHC class II, FITC anti-CD80, FITC anti-CD86, and PE anti-CD11c.

Human peripheral blood cells were analyzed by three-color flow cytometry as reported previously. Human mDCs and pDCs were defined as Lin1−/HLA-DR+ /CD11c+ and Lin1−/HLA-DR+/CD123+, respectively. Murine splenic DCs were identified as CD11c+ cells and the surface markers were incubated with anti-mouse MHC-II and CD86, respectively. Flow cytometry was performed on a FACS Caliber flow cytometer and analyzed with CellQuest Pro software (Becton Dickinson).

Mixed lymphocyte reaction (MLR) assay

An MLR assay was used to evaluate the stimulation of DCs with allogeneic and syngeneic T-cell proliferation. On day 6, after treatment with mitomycin C (25 μg/mL) for 2 h to arrest cell proliferation, DCs without transfaction or transfected with negative control siRNA or GALNT4 siRNA were serum-starved for 6 h and then treated with P-selectin (100 ng/mL; Sigma-Aldrich), or KPL1 (5 μg/mL, a monoclonal Ab against PSGL-1; Santa Cruz Biotechnology, Inc., Dallas, TX, USA) for 24 h. DCs (concentrations ranging from 1 × 105 to 1 × 106/mL) were then cocultured with CD4+ T cells (5 × 106/mL) in 96-well plates for 3 days. T-cell proliferation was determined by the cell counting kit (CCK)-8 method. Following incubation for 1 h with CCK-8 solution, the optical density of the wells was measured at a wave length of 450 nm using a microplate reader.

Cell adhesion assay

On day 6, DCs were treated as described for the MLR assay. After 24 h, the DCs were harvested and prestained with 5 mol/L of calcein-AM (Sigma-Aldrich) for 30 min at 37 °C. HUVECs were activated by pretreatment with TNF-α (1 ng/mL, R&D system) for 6 h. After washing with phosphate-buffered saline, fluorescently labeled DCs were added onto the HUVEC monolayers at a density of 1 × 106 cells/mL. Non-adherent monocytes were washed away after 30 min and adhesion was quantified by counting fluorescent monocytes attached to the endothelium.

Cell migration assay

Cell migration was determined in transwell chambers (Corning Costar, 8 μm; Corning, Inc., Corning, NY, USA). DCs were treated as described for the MLR assay. Then, 3 × 104 cells were seeded in the upper chamber and complete medium containing 100 ng/mL of CCL21 (R&D Systems) was added into the lower chamber. Cell migration was allowed to proceed for 12 h. Cells that migrated to the lower surface of the filter were fixed with 4% formaldehyde, stained with 1% crystal violet, and quantified by cell counting under high magnification.

Western blot analysis

The total protein concentration was measured using a bicinchoninic acid assay kit (Beyotime Institute of Biotechnology, Haimen, China). In brief, 30 μg of proteins were loaded into each lane of sodium dodecyl sulfate polyacrylamide gels, separated by electrophoresis, and then transferred to polyvinylidene fluoride membranes (Pall Corporation, Beijing, China), which were incubated with primary Abs against IRAK4, phospho-IRAK4, P38, phospho-P38, JNK, phospho-JNK, TRIF, IRF3, phospho-IRF3, NF-κB p65, phospho-NF-κB p65, IKKα, IKKβ, phospho-IKKα/β, IκBα, and phospho-IκBα (Cell Signaling Technology, Inc., Beverly, MA, USA; all diluted to 1:1000), as well as GAPDH (1:5000) and PSGL-1 (Santa Cruz Biotechnology, Inc.; 1:1000). Anti-rabbit or mouse horseradish peroxidase-linked Ab (ZSGB-BIO Technology Co., Ltd., Beijing, China; 1:8000) was used as the secondary Ab. Detection was performed using a chemiluminescence kit (Advansta, Inc., Menlo Park, CA, USA). Densitometry of proteins was analyzed with Gel-Pro software (Media Cybernetics).

Statistical analysis

All data analyses were performed using IBM SPSS Statistics for Windows, version 21.0 (IBM Corporation, Armonk, NY, USA). Categorical data are expressed as numbers and percentages or ratios and were compared using the chi-square test. Continuous data are expressed as the mean ± standard deviation (SD) and were compared if normally distributed with homogenous sample variance using the independent sample t-test; otherwise, the rank sum test was used. Statistical significance was determined by single factor analysis of variance with Bonferroni correction. Spearman’s rank correlation coefficient was used to assess the correlation between patient serum P-selectin levels and the mDC/pDC ratio. A two-tailed probability (p) value of <0.05 was considered statistically significant.

Acknowledgements

This project was funded by the National Natural Science Foundation of China (grant nos. 81100220, 81670324, and 81770340).
L-selectin promotes the growth of capillary walls in atherosclerotic plaques, which may contribute to the development of atherosclerosis. This effect is highlighted in the study by Ye et al. from the Cardiac Center/Division of Cardiovascular Diseases, Beijing Friendship Hospital, and colleagues. They investigated the role of L-selectin in the progression of atherosclerosis in mice. The study found that L-selectin promotes the growth of atherosclerotic plaques, indicating a potential therapeutic target for the treatment of atherosclerosis.

References:
1. Chistiakov, D. A., Sobol, I. A., Grekov, A. N. & Bobryshev, Y. V. Dendritic cells in atherosclerotic inflammation: the complexity of functions and the peculiarities of pathophysiological effects. Front. Physiol. 5, 196 (2014).
2. Cybulsky, M. I., Cheong, C. & Robbins, C. S. Macrophages and dendritic cells: partners in atherogenesis. Circ. Res. 118, 637–662 (2016).
3. Melman, I. & Steinman, R. M. Dendritic cells: specialized and regulated antigen processing machines. Cell 106, 255–258 (2001).
4. Liu, K. et al. Immune tolerance after delivery of dying cells to dendritic cells in situ. J. Exp. Med. 196, 1091 (2002).
5. Erbel, C. et al. Functional profile of activated dendritic cells in unstable atherosclerotic plaque. Basic Res. Cardiol. 102, 123 (2007).
6. Yilmaz, A. et al. Emergence of dendritic cells in rupture-prone regions of vulnerable carotid plaques. Atherosclerosis 176, 101–110 (2004).
7. Vestweber, D. & Blanks, J. E. Mechanisms that regulate the function of the selectins and their ligands. Physiol. Rev. 79, 181 (1999).
8. Burger, P. C. & Wagner, D. D. Platelet-P-selectin facilitates atherosclerotic lesion development. Blood 101, 2661–2666 (2003).
9. Panek, S. R. et al. Circulating soluble P-selectin must dimerize to promote inflammation and coagulation in mouse. Blood 130, 181–191 (2017).
10. Ridker, P. M., Buring, J. E. & Rifai, N. Soluble P-selectin and the risk of future cardiovascular events. Circulation 103, 491 (2001).
11. Taras, J. C. et al. Effects of the P-selectin antagonist inclucamab on myocardial damage after percutaneous coronary intervention for non-ST-segment elevation myocardial infarction results of the SELECT-ACTS Trial. J. Am. Coll. Cardiol. 61, 2046–2055 (2013).
12. Iwasaki, A. & Medzhitov, R. Toll-like receptor control of the adaptive immune response. Nat. Immunol. 5, 987–995 (2004).
13. Ozaki, Y. et al. Association between P-selectin glycoprotein ligand-1 and pathogenesis in acute coronary syndrome assessed by optical coherence tomography. Atherosclerosis 233, 697–703 (2014).
14. Ye, Z., Liu, J., Zheng, J., Zhang, J. & Huang, R. L-selectin promotes the maturation of dendritic cells via up-regulation of the expression of TLR4 in vitro. Annals Clin. Lab. Sci. 47, 389–394 (2017).
15. Neumann, M. et al. Differential expression of Rel/NF-kappaB and octamer factors is a hallmark of the generation and maturation of dendritic cells. Blood 95, 277 (2000).
16. Akira, S. & Takeuchi, K. Toll-like receptor signalling. Nat. Rev. Immunol. 4, 499–511 (2004).
17. Kagan, J. C. & Medzhitov, R. Phosphoinositide-mediated adaptor recruitment controls Toll-like receptor signaling. Cell 125, 943–955 (2006).
18. Li, B. et al. The metabonomics study of P-selectin glycoprotein ligand-1 (PSGL-1) deficiency inhibiting the progression of atherosclerosis in LDLR(-/-) mice. Int. J. Biol. Sci. 14, 35–46 (2018).
19. Manka, D., Collins, R. G., Ley, K., Beaudet, A. L. & Sarembock, I. J. Absence of P-selectin, but not intercellular adhesion molecule-1, attenuates neointimal growth after arterial injury in apolipoprotein e-deficient mice. Circulation 103, 1000 (2001).
20. An, G. et al. P-selectin glycoprotein ligand-1 is highly expressed on Ly-6Chi monocytes and a major determinant for Ly-6Chi monocyte recruitment to sites of atherosclerosis in mice. Circulation 117, 3227 (2008).
21. Luo, W. et al. P-selectin glycoprotein ligand-1 deficiency leads to cytokine resistance and protection against atherosclerosis in apolipoprotein E deficient mice. Atherosclerosis 220, 110–117 (2012).
22. Packard, R. R. S., Lichtman, A. H. & Libby, P. Innate and adaptive immunity in atherosclerosis. Semin. Immunopathol. 31, 5 (2009).
23. Cybulsky, M. I., Cheong, C. & Robbins, C. S. Macrophages and dendritic cells: partners in atherogenesis. Circ. Res. 118, 637 (2016).
24. Yao, K. et al. Changes of dendritic cells and f automobile in type 2 diabetic patients with unstable angina pectoris: a preliminary report. Cardiovasc. Diabetol. 10, 50 (2011).
25. Yilmaz, A. et al. Decrease in circulating myeloid dendritic cell precursors in coronary artery disease. J. Am. Coll. Cardiol. 48, 70–80 (2006).
26. Sugiyama, T. et al. Reduction and activation of circulating dendritic cells in patients with coronary artery disease. Circulation 118, 2048–2058 (2008).
27. Shimomura, H. et al. Sialyltransferase expression and maturation of dendritic cells in patients with unstable angina pectoris. J. Clin. Pathol. 57, 67–73 (2004).
28. Kadokawa, N. et al. Subsets of human dendritic cell precursors express different toll-like receptors and respond to different microbial antigens. J. Exp. Med. 194, 863–869 (2001).
29. Gautier, E. L. et al. Conventional dendritic cells at the crossroads between immunity and cholesterol homeostasis in atherosclerosis. Circulation 119, 2367 (2009).
30. Alexander, N. et al. Pathogen-sensing plasmacytoid dendritic cells stimulate cytotoxic T-cell function in the atherosclerotic plaque through interferon-alpha. Circulation 114, 2482–2489 (2007).
31. Daissaromma, J. T. M. N. et al. Plasmacytoid dendritic cells protect against atherosclerosis by tuning T-cell proliferation and activity. Circ. Res. 109, 1387–1395 (2011).
32. Z. L. et al. P-selectin glycoprotein ligand-1 is broadly expressed in cells of myeloid, lymphoid, and dendritic lineage and in some nonhemopoietic cells. Blood 88, 3010–3021 (1996).
33. Julienne, S. et al. Sialyl Lewis(x) on P-selectin glycoprotein ligand-1 is regulated during differentiation and maturation of dendritic cells: a mechanism involving the glycosyltransferases C2GnT1 and ST3Gal I. J. Immunol. 179, 5701 (2007).
34. Tanico, R., Otero, D. C., Takahashi, A. A. & Bradley, L. M. P-Selectin: a new player in the immune checkpoint landscape. Trends Immunol. 38, 323–335 (2017).
35. Matsumoto, M., Miyasaka, M. & Hirata, T. P-selectin glycoprotein ligand-1 negatively regulates T-cell immune responses. J. Immunol. 183, 7204–7211 (2009).
36. Weyrich, A. S., McIntyre, T. M., McEver, R. P., Prescott, S. M. & Zimmerman, G. A. Monocyte tethering by P-selectin regulates monocyte chemotactic protein-1 and tumor necrosis factor-alpha secretion. Signal integration and NF-kappa B translocation. J. Clin. Investig. 95, 2303–2305 (1995).
37. Xu, T. et al. P-selectin cross-links PSGL-1 and enhances neutrophil adhesion to fibrinogen and ICAM-1 in a Src kinase-dependent, but GPCR-independent mechanism. Cell. Adhes. Migr. 1, 115–123 (2007).
38. Urzaizqui, A. et al. Functional role of P-selectin glycoprotein ligand 1/P-selectin interaction in the generation of tolerogenic dendritic cells. J. Immunol. 179, 7457 (2007).
39. Zhou, T. et al. The inhibitory effects of anti-P-selectin lectin-EGF monoclonal antibody on maturation and function of human dendritic cells. Chin. J. Cell Biol. 28, 201–205 (2006).
40. Hidari, K., I. Weyrich, A. S., Zimmerman, G. A. & McEver, R. P. Engagement of P-selectin glycoprotein ligand-1 enhances tyrosine phosphorylation and activates mitogen-activated protein kinases in human neutrophils. J. Biol. Chem. 272, 28750–28756 (1997).
41. Patel, M. S., Miranda-Nieves, D., Chen, J., Haller, C. A. & Chakof, E. L. Targeting P-selectin glycoprotein ligand-1/P-selectin interactions as a novel therapy for metabolic syndrome. Transl. Res. J. Lab. Clin. Med. 183, 1–13 (2017).
42. Gremmell, T. et al. Impact of variables of the P-selectin—P-selectin glycoprotein ligand-1 axis on leukocyte-platelet interactions in cardiovascular disease. Thromb. Haemost. 113, 806–812 (2015).
43. Wagner, G. K. Downregulation of P-selectin glycoprotein ligand-1 as a potential anti-inflammatory mechanism. Future Med. Chem. 9, 1323–1326 (2017).
44. Niessner, A. et al. Synergistic proinflammatory effects of the antiviral cytokine interferon-α and toll-like receptor 4 ligands in the atherosclerotic plaque. *Circulation* **116**, 2043 (2007).

45. Babazada, H., Yamashita, F. & Hashida, M. Suppression of experimental arthritis with self-assembling glycol-split heparin nanoparticles via inhibition of TLR4-NF-κB signaling. *J. Control Release* **194**, 295–300 (2014).

46. Harari, O. A., Alcaide, P., Ahn, D., Luscinskas, F. W. & Liao, J. K. Absence of TRAM restricts toll-like receptor 4 signaling in vascular endothelial cells to the MyD88 pathway. *Circ. Res.* **98**, 1134 (2006).

47. Fang, H. et al. TLR4 is essential for dendritic cell activation and anti-tumor T-cell response enhancement by DAMPs released from chemically stressed cancer cells. *Cell. Mol. Immunol.* **11**, 150–159 (2014).

48. Illario, M. et al. Calmodulin-dependent kinase IV links toll-like receptor 4 signaling with survival pathway of activated dendritic cells. *Blood* **111**, 723 (2008).

49. Ling, G. S. et al. Integrin CD11b positively regulates TLR4-induced signalling pathways in dendritic cells but not in macrophages. *Nat. Commun.* **5**, 3039 (2014).

50. Gong, Y. et al. Dynamic contributions of P- and E-selectins to beta2-integrin-induced neutrophil transmigration. *FASEB J.* **31**, 212–223 (2017).

51. Ma, Y. Q., Plow, E. F. & Geng, J. G. P-selectin binding to P-selectin glycoprotein ligand-1 induces an intermediate state of alphabeta2 activation and acts cooperatively with extracellular stimuli to support maximal adhesion of human neutrophils. *Blood* **104**, 2549 (2004).

52. O’Gara, P. T. et al. 2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. *J. Am. Coll. Cardiol.* **61**, 78–140 (2013).